PathBank

Pathway Description

Finafloxacin Action Pathway

Haemophilus influenzae

Category:

Metabolite Pathway

Sub-Category:

Drug Action

Created: 2023-09-01

Last Updated: 2023-11-27

Finafloxacin is a fluoroquinolone antibiotic agent used to treat cute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin inhibits DNA gyrase (topoisomerase II) and topoisomerase IV. These proteins prevent supercoiling in bacterial DNA. The inhibition of DNA gyrase (topoisomerase II) and topoisomerase IV causes supercoiling of the bacterial DNA. This prevents DNA replication.

References

Finafloxacin Pathway References

Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.

Pubmed: 29126136

McKeage K: Finafloxacin: first global approval. Drugs. 2015 Apr;75(6):687-93. doi: 10.1007/s40265-015-0384-z.

Pubmed: 25808831

Highlighted elements will appear in red.

Highlight Compounds

	Finafloxacin
	Magnesium

Highlight Proteins

	DNA topoisomerase 4 subunit A
	DNA topoisomerase 4 subunit B

Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.

Visualize Compound Data